Genetics Firm Gets Baby-Predicting Patent

23andMe denies that its new patent will be used to help couples create designer babies based on personal genetic testing.

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WIKIMEDIA, SCA SVENSKA CELLULOSA AKTIEBOLAGETThe patent awarded to California-based genetic testing company 23andMe for its “Family Traits Inheritance Calculator” sounded to some bioethicists a lot like a green light for making designer babies based on the genetic profiles of couples seeking to procreate. And for good reason. The patent application, filed by 23andMe more than five years ago, basically lays out a blueprint for how prospective parents could use the company’s technology to choose which gametes to use in an in vitro fertilization scenario to get just the baby they wanted. A child’s eye color, lactose tolerance, and earwax consistency are just few of the traits that 23andMe’s calculator can predict, according to the patent.

“What 23andMe is claiming is a method by which prospective donors of ova and/or sperm may be selected so as to increase the likelihood of producing a human baby with characteristics desired by the prospective parents, the selection being based on a computerized comparison of the genotypic data of the egg provider with that of the sperm provider,” wrote Sigrid Sterckx, a bioethicist at Ghent University in Belgium, and a trio of coauthors in an opinion piece published yesterday (October 3) in Genetics in Medicine. “We cannot elaborate here on this debate, but it is clear that selecting children in ways such as those patented by 23andMe is hugely ethically controversial,” the authors continued. “The use of preimplantation genetic diagnosis to avoid implantation of embryos ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide